The estimated Net Worth of George Yancopoulos is at least $1.25 Billion dollars as of 16 May 2024. George Yancopoulos owns over 50,000 units of Regeneron Pharmaceuticals stock worth over $897,616,875 and over the last 21 years he sold REGN stock worth over $329,720,774. In addition, he makes $20,664,100 as President, Chief Scientific Officer, and Director at Regeneron Pharmaceuticals.
George has made over 48 trades of the Regeneron Pharmaceuticals stock since 2003, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of REGN stock worth $48,636,500 on 16 May 2024.
The largest trade he's ever made was exercising 442,267 units of Regeneron Pharmaceuticals stock on 22 December 2021 worth over $97,776,388. On average, George trades about 66,280 units every 113 days since 2003. As of 16 May 2024 he still owns at least 786,383 units of Regeneron Pharmaceuticals stock.
You can see the complete history of George Yancopoulos stock trades at the bottom of the page.
Dr. George D. Yancopoulos M.D., Ph.D. serves as President, Chief Scientific Officer, Director of the Company. Dr. Yancopoulos joined Dr. Schleifer in 1989 as founding scientist of the Company, and together they built and have managed the Company since then. Dr. Yancopoulos is currently President and Chief Scientific Officer, and has served on the board since 2001. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the five FDA-approved drugs the Company has developed, EYLEA® (aflibercept) Injection, Praluent® (alirocumab) Injection, Dupixent® (dupilumab) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use, as well as of its foundation technologies, including the TRAP technology, VelociGene®, and VelocImmune®. As one of the few members of the National Academy of Sciences from industry and as an author of a substantial number of scientific publications, Dr. Yancopoulos has a distinguished record of scientific expertise. Dr. Yancopoulos also brings to the board his experience in building and managing the Company, his in-depth knowledge of the Company’s technologies and research and development programs, and his proven track-record for envisioning successful long-term strategic directions and opportunities.
As the President, Chief Scientific Officer, and Director of Regeneron Pharmaceuticals, the total compensation of George Yancopoulos at Regeneron Pharmaceuticals is $20,664,100. There are 2 executives at Regeneron Pharmaceuticals getting paid more, with P. Roy Vagelos having the highest compensation of $22,304,300.
George Yancopoulos is 60, he's been the President, Chief Scientific Officer, and Director of Regeneron Pharmaceuticals since 2016. There are 14 older and 7 younger executives at Regeneron Pharmaceuticals. The oldest executive at Regeneron Pharmaceuticals, Inc. is P. Roy Vagelos, 90, who is the Chairman of the Board, Director.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis, and Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: